Purpose: Transversus abdominis plane (TAP) block is a widely accepted technique for postoperative pain management in kidney transplant (KT) patients, typically with 0.25– 0.5% bupivacaine. Lower concentrations, such as 0.125%, may reduce systemic toxicity while remaining effective. This study aimed to compare the efficacy and safety of 0.125% versus 0.25% bupivacaine for TAP block in KT patients. Patients and Methods: In this prospective, double-blind, randomized trial, KT patients received either 0.125% or 0.25% bupivacaine for ultrasound-guided TAP block prior to surgery, followed by intravenous fentanyl patient-controlled analgesia postoperatively. The primary outcome was 24-hour fentanyl consumption. Secondary outcomes included intraoperative fentanyl use, time to first analgesic request, pain scores, TAP block complications, opioid-related side effects, and patient satisfaction. Results: Seventy-six patients were enrolled, with 74 completing the study (37 per group). Baseline characteristics were comparable between groups. Intraoperative fentanyl use was significantly lower in the 0.25% bupivacaine group (140.5 ± 39.7 mcg) compared to the 0.125% group (166.8 ± 44.7 mcg; P = 0.009). However, 24-hour postoperative fentanyl consumption did not differ significantly, with the 0.125% group using 201.5 ± 110.4 mcg and the 0.25% group using 177.3 ± 104.1 mcg (mean difference: − 24.2; 95% CI: − 73.9 to 25.5; P = 0.335). The 0.25% group had a longer median time to first analgesic request (15 vs 10 minutes; P = 0.020). Postoperative pain scores, TAP block complications, and patient satisfaction were similar between groups. Conclusion: TAP block with 0.125% bupivacaine provided comparable postoperative opioid consumption and pain scores to 0.25%, without associated complications. Keywords: transversus abdominis plane block, TAP block, bupivacaine, kidney transplant, renal transplant, postoperative pain, opioid consumption
Nonphiaraj et al. (2026) studied this question.